BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao W, Leroux S, Jacqz-Aigrain E. Dosage individualization in children: integration of pharmacometrics in clinical practice. World J Pediatr 2014;10:197-203. [PMID: 25124969 DOI: 10.1007/s12519-014-0493-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Leroux S, Elie V, Zhao W, Magreault S, Jacqz-aigrain E. Principles and applications of pharmacometrics in drug evaluation in children. Therapies 2018;73:165-70. [DOI: 10.1016/j.therap.2017.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Matera MG, Rogliani P, Ora J, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opin Pharmacother 2018;19:2043-53. [PMID: 30359143 DOI: 10.1080/14656566.2018.1534957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Leroux S, Jacqz-Aigrain E, Biran V, Lopez E, Madeleneau D, Wallon C, Zana-Taïeb E, Virlouvet AL, Rioualen S, Zhao W. Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. Antimicrob Agents Chemother 2016;60:2039-42. [PMID: 26787690 DOI: 10.1128/AAC.02214-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
4 Leroux S, Roué JM, Gouyon JB, Biran V, Zheng H, Zhao W, Jacqz-Aigrain E. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. Antimicrob Agents Chemother 2016;60:6626-34. [PMID: 27572399 DOI: 10.1128/AAC.01045-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
5 Wang YK, Wu YE, Li X, Tian LY, Khan MW, Tang BH, Shi HY, Zheng Y, Hao GX, van den Anker J, You DP, Zhao W. Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis. Antimicrob Agents Chemother 2020;64:e01412-20. [PMID: 32816735 DOI: 10.1128/AAC.01412-20] [Reference Citation Analysis]
6 Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. J Antimicrob Chemother 2019;74:2128-38. [PMID: 31049551 DOI: 10.1093/jac/dkz158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
7 Guilhaumou R, Marsot A, Dupouey J, Galambrun C, Boulamery A, Coze C, Simon N, André N. Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization. Ther Drug Monit 2016;38:559-66. [PMID: 27631462 DOI: 10.1097/FTD.0000000000000318] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Germovsek E, Barker CIS, Sharland M, Standing JF. Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. Clin Pharmacokinet 2019;58:39-52. [PMID: 29675639 DOI: 10.1007/s40262-018-0659-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
9 Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. Clin Pharmacokinet 2015;54:1183-204. [PMID: 26138291 DOI: 10.1007/s40262-015-0298-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 9.7] [Reference Citation Analysis]
10 Vermeulen E, van den Anker JN, Della Pasqua O, Hoppu K, van der Lee JH; Global Research in Paediatrics (GRiP). How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians. J Pharm Pharmacol 2017;69:439-47. [PMID: 27671925 DOI: 10.1111/jphp.12637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
11 Zhao W, Zhang D, Storme T, Baruchel A, Declèves X, Jacqz-Aigrain E. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. Br J Clin Pharmacol 2015;80:1197-207. [PMID: 26138279 DOI: 10.1111/bcp.12710] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
12 Zhou J, Jiang L, Zhang ZL, Wang ZR, Zhang YX, Lin X, Tang BH, Yao BF, Guo ZX, Yang JJ, Van Den Anker J, Wu YE, Zhao W. Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants. J Antimicrob Chemother 2022:dkac176. [PMID: 35662337 DOI: 10.1093/jac/dkac176] [Reference Citation Analysis]
13 Li X, Qi H, Jin F, Yao BF, Wu YE, Qi YJ, Kou C, Wu XR, Luo XJ, Shen YH, Zheng X, Wang YH, Xu F, Jiao WW, Li JQ, Xiao J, Dong YN, Du B, Shi HY, Xu BP, Shen AD, Zhao W. Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis. Eur J Pharm Sci 2021;163:105868. [PMID: 33951483 DOI: 10.1016/j.ejps.2021.105868] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]